Elranatamab pharmacokinetics.
tumor necrosis
TUMOR NECROSIS
A priming dose was not administered during dose escalation (part 1), whereas a single priming dose of 600 µg kgSerum cytokines, including those produced by activated T cells, were increased after the first dose of elranatamab. Consistent with mitigation of clinical CRS, elevated serum levels of cytokines, including interferon-gamma, interleukin-2, tumor necrosis factor-alpha and interleukin-6, were observed in part 1.1 after the priming dose but then substantially attenuated at the RP2D (Extended Data Fig. 